Navigation Links
Pregis Announces First Quarter 2008 Financial Results
Date:5/9/2008

>

Property, plant and

equipment, net 287,651 277,398

Other assets

Goodwill 153,803 150,000

Intangible assets, net 48,380 47,910

Deferred financing

costs, net 9,515 10,080

Due from Pactiv, long-

term 11,553 12,229

Pension and related

assets 26,741 25,659

Other 1,649 2,313

Total other assets 251,641 248,191

Total assets $890,754 $855,319

Liabilities and

stockholder's equity

Current liabilities

Current portion of

long-term debt $3,982 $2,120

Accounts payable 116,443 100,326

Accrued income taxes 8,519 13,900

Accrued payroll and

benefits 17,662 19,814

Accrued interest 11,684 6,775

Other 22,201 22,436

Total current

liabilities 180,491 165,371

Long-term debt 495,013 475,604

Deferred income taxes 37,294 34,589

Long-term income tax

liabilities 9,781 9,585

Pension and related

liabiliti
'/>"/>

SOURCE Pregis Corporation
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine news :

1. Pregis Corporation Appoints New President of Protective Packaging North America
2. Pregis Announces Investor Conference Call to Review 2007 Fourth Quarter and Full Year Financial Results
3. Pregis Announces Fouth Quarter and Full Year 2007 Financial Results
4. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
5. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
6. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
7. HEI, Inc. Announces Sale of RFID Division Assets
8. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
9. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
10. Z Trim Announces Revocation of Gregory Halpern Severence Agreement
11. Brooke Franchise Corporation Announces Selected July Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/16/2008)...nce-promising drug formerly approved as a second l...a, enhanced the effectiveness of hormonal therapy ...breast cancer, according to a Phase II clinical tr...M. D. Anderson Cancer Center. , These findings a...dy for Iressa in breast cancer, as well as for the...
(Date:5/16/2008)...USNewswire/ -- Behavioral healthcare,systems are p...the millions,of Americans of all ages who experien...ear, according to the latest annual survey from th...ms (NAPHS) released today., The 2007 NAPHS Annual...healthcare delivery. One chapter provides a trend ...
(Date:5/16/2008)...of Nomura Code Securities Limited as ... May 16 /PRNewswire-FirstCall/ -- Medicsight PLC, ...x: MGT ) (the "Company"), and an,industry leader ...D) and,image analysis software which assists in th...announced the appointment of NM Rothschild & Sons ...
(Date:5/16/2008)...wire/ -- Tao Formulations announces the,official l...t the Internal,Medicine 2008 conference in Washing...ion of years of research to develop a safe, all-na...r relieving menopausal symptoms., Company founder...ician,and gynecologist, founded Tao Formulations ...
Breaking Medicine News(10 mins):Health News:Iressa shows promise for treatment of metastatic breast cancer when combined with hormonal therapy 2Health News:Iressa shows promise for treatment of metastatic breast cancer when combined with hormonal therapy 3Health News:New NAPHS Annual Survey Tracks Behavioral Treatment Trends 2Health News:Medicsight Announces Appointment of NM Rothschild & Sons Limited as Corporate Adviser 2Health News:Medicsight Announces Appointment of NM Rothschild & Sons Limited as Corporate Adviser 3Health News:Tao Formulations Announces the Official Launch of Tao Harmony - Menopause Relief Formula 2
...(Jawaharlal Institute of Postgraduate Medical Coll...day //long strike to protest against the governmen...her educational institutes. A spokesman of the As...t they had submitted a memo to the government to h...
...triking medicos to immediately call off their 20-d...and resume work within three days. The court - whi... also warned that strong action will be taken if i...ed. "We direct that all strikes, protests and dem...
...eat diabetic nerve damage has shown promising resu...s// of the University of Manchester, when injected...ular gene responsible to prevent nerve damage in h...he positive preclinical results – reported in the ...
...Centrally administered Jawaharlal Nehru Institute ...IPMER) // in Pondicherry today began a 48-hour lon...te educational institutions. A batch of resident ...ast inside the campus urging the Centre to review ...
Other Medicine News:Health News:New Gene Therapy Treats Diabetic Neuropathy 2
(Date:5/15/2008)...ay 15 /- Eisai Corporation of North,A...al data abstracts about,compounds in the company,s...cal oncology research have been accepted for prese... Society of Clinical Oncology (ASCO),taking place...variety of abstracts on Eisai marketed products an...
(Date:5/15/2008)...ical Data from Prostate, Colorectal and Ovarian ...to Hold Investor Event on Sun., June 1 with Oncolo... /- Poniard,Pharmaceuticals...ny focused,on oncology, today announced that the C...s of picoplatin, in various tumor types and combin...
(Date:5/15/2008)...5 /- Schering-Plough,Corpor...ence and treatment of,chronic hepatitis C virus (H...ral clinical studies with PEGINTRON(TM) (peginterf...ination therapy, as well as boceprevir, the,compan...ill be presented at,the 39th annual Digestive Dise...
(Date:5/15/2008)...ULOUSE, France, May 15 /- Cerenis,The...tical company,developing HDL-related compounds for...eases, today announced that it has completed a Pha...y,s lead product candidates.,CER-002 is a peroxiso...ecific agonist in development for the treatment of...
Breaking Medicine Technology:Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 2Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 3Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 4Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 5Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 6Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 7Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting 8Poniard to Present Clinical Data From Picoplatin Trials in Multiple Tumor Types at American Society of Clinical Oncology 2008 Annual Meeting 2Poniard to Present Clinical Data From Picoplatin Trials in Multiple Tumor Types at American Society of Clinical Oncology 2008 Annual Meeting 3Poniard to Present Clinical Data From Picoplatin Trials in Multiple Tumor Types at American Society of Clinical Oncology 2008 Annual Meeting 4Poniard to Present Clinical Data From Picoplatin Trials in Multiple Tumor Types at American Society of Clinical Oncology 2008 Annual Meeting 5Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting 2Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting 3Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting 4Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting 5Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting 6Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting 7Cerenis Therapeutics Completes Phase I Clinical Trial of CER-002 for Treatment of Cardiovascular Disease 2Kaiser Permanente Study Shows Newer Stronger Evidence That Caffeine During Pregnancy Increases Miscarriage Risk 2671 1Kaiser Permanente Study Shows Newer Stronger Evidence That Caffeine During Pregnancy Increases Miscarriage Risk 2671 2Kaiser Permanente Study Shows Newer Stronger Evidence That Caffeine During Pregnancy Increases Miscarriage Risk 2671 3Kaiser Permanente Study Shows Newer Stronger Evidence That Caffeine During Pregnancy Increases Miscarriage Risk 2671 4Kaiser Permanente study shows link between caffeine and miscarriage 9813 1Kaiser Permanente study shows link between caffeine and miscarriage 9813 2Kaiser Permanente study shows link between caffeine and miscarriage 9813 3Pros cons of drug proven to prevent prostate cancer should be considered researchers recommend 9810 1Pros cons of drug proven to prevent prostate cancer should be considered researchers recommend 9810 2NEWSWEEK 3A Media Lead Sheet January 28 2008 Issue 28on newsstands Monday January 21 29 9809 1NEWSWEEK 3A Media Lead Sheet January 28 2008 Issue 28on newsstands Monday January 21 29 9809 2NEWSWEEK 3A Media Lead Sheet January 28 2008 Issue 28on newsstands Monday January 21 29 9809 3NEWSWEEK 3A Media Lead Sheet January 28 2008 Issue 28on newsstands Monday January 21 29 9809 4NEWSWEEK 3A Media Lead Sheet January 28 2008 Issue 28on newsstands Monday January 21 29 9809 5
...gned to provide functional management of stress fr...able fractures of the lower leg.,The Leg Brace fea...patented Duplex™ aircell system. This exclus...ng aircells, distal and proximal, that provide sup...
...s available with optional hot and cold therapy Gel...roviding cold therapy to reduce swelling and /or h...covery.,To order hot and cold therapy gel pad, pla...o fit., ,Our Patented Formfit 3-dimensional moldi...
Bird and Cronin, Inc. is a leading manufacturer of Patient Footwear, Orthopedic Softgoods, and Specialty Patient Care Products. Our products are of the highest quality and available in the USA and In
FREEDOM® Memory Thumb Spica lets you make a custom splint in minutes. Immerese in 160 F water until pliable, and remove. Amazingly, it maintains its shape and is ready to be precisely, profession
Medicine Products: